Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer von KONECNY, Gottfried E, CHEN WANG, GOSTOUT, Bobbie, PODRATZ, Karl C, KEENEY, Gary, WANG, He-Jing, HARTMANN, Lynn C, SLAMON, Dennis J, GOODE, Ellen L, HAMIDI, Habib, WINTERHOFF, Boris, KALLI, Kimberly R, DERING, Judy, GINTHER, Charles, CHEN, Hsiao-Wang, DOWDY, Sean, CLIBY, William

Volltext

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro von Finn, Richard S, Dering, Judy, Conklin, Dylan, Kalous, Ondrej, Cohen, David J, Desai, Amrita J, Ginther, Charles, Atefi, Mohammad, Chen, Isan, Fowst, Camilla, Los, Gerret, Slamon, Dennis J

Volltext

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07) von Hurvitz, Sara A., Caswell-Jin, Jennifer L., McNamara, Katherine L., Zoeller, Jason J., Bean, Gregory R., Dichmann, Robert, Perez, Alejandra, Patel, Ravindranath, Zehngebot, Lee, Allen, Heather, Bosserman, Linda, DiCarlo, Brian, Kennedy, April, Giuliano, Armando, Calfa, Carmen, Molthrop, David, Mani, Aruna, Chen, Hsiao-Wang, Dering, Judy, Adams, Brad, Kotler, Eran, Press, Michael F., Brugge, Joan S., Curtis, Christina, Slamon, Dennis J.

Volltext

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer von DI LEO, Angelo, GOMEZ, Henry L, WILLIAMS, Lisa S, DERING, Judy, FINN, Richard S, PRESS, Michael F, AZIZ, Zeba, ZVIRBULE, Zanete, BINES, Jose, ARBUSHITES, Michael C, GUERRERA, Stephanie F, KOEHLER, Maria, OLIVA, Cristina, STEIN, Steven H

Volltext

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/ triple-negative breast cancer cell lines growing in... von FINN, Richard S, DERING, Judy, GINTHER, Charles, WILSON, Cindy A, GLASPY, Padraic, TCHEKMEDYIAN, Nishan, SLAMON, Dennis J

Volltext

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer von KONECNY, Gottfried E, WINTERHOFF, Boris, KALLI, Kimberly R, FINN, Richard S, GINTHER, Charles, JONES, Siân, VELCULESCU, Victor E, RIEHLE, Darren, CLIBY, William A, RANDOLPH, Sophia, KOEHLER, Maria, HARTMANN, Lynn C, KOLAROVA, Teodora, SLAMON, Dennis J, JINGWEI QI, MANIVONG, Kanthinh, DERING, Judy, GUORONG YANG, CHALUKYA, Meenal, WANG, He-Jing, ANDERSON, Lee

Volltext

Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy von Zoeller, Jason J, Press, Michael F, Selfors, Laura M, Dering, Judy, Slamon, Dennis J, Hurvitz, Sara A, Brugge, Joan S

Volltext

Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer von Cohen, Brenda, Shimizu, Mamiko, Izrailit, Julia, Ng, Nancy F. L, Buchman, Yuri, Pan, James G, Dering, Judy, Reedijk, Michael

Volltext

Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomize... von FINN, Richard S, PRESS, Michael F, DERING, Judy, ARBUSHITES, Michael, KOEHLER, Maria, OLIVA, Cristina, WILLIAMS, Lisa S, DI LEO, Angelo

Volltext

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244) von DRY, Jonathan R, PAVEY, Sandra, GRAHAM, Alexander, BERAN, Garry, CASSIDY, Andrew, HAGGERTY, Carolyn, BROWN, Helen, ELLISON, Gillian, DERING, Judy, TAYLOR, Barry S, STARK, Mitchell, BONAZZI, Vanessa, PRATILAS, Christine A, RAVISHANKAR, Sugandha, PACKER, Leisl, FENG XING, SOLIT, David B, FINN, Richard S, ROSEN, Neal, HAYWARD, Nicholas K, FRENCH, Tim, SMITH, Paul D, HARBRON, Chris, RUNSWICK, Sarah, HODGSON, Darren, CHRESTA, Christine, MCCORMACK, Rose, BYRNE, Natalie, COCKERILL, Mark

Volltext

Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures von Winterhoff, Boris, Hamidi, Habib, Wang, Chen, Kalli, Kimberly R, Fridley, Brooke L, Dering, Judy, Chen, Hsiao-Wang, Cliby, William A, Wang, He-Jing, Dowdy, Sean, Gostout, Bobbie S, Keeney, Gary L, Goode, Ellen L, Konecny, Gottfried E

Volltext

In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response von Hurvitz, Sara A., Kalous, Ondrej, Conklin, Dylan, Desai, Amrita J., Dering, Judy, Anderson, Lee, O’Brien, Neil A., Kolarova, Teodora, Finn, Richard S., Linnartz, Ronald, Chen, David, Slamon, Dennis J.

Volltext

The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth von Garon, Edward B, Finn, Richard S, Hamidi, Habib, Dering, Judy, Pitts, Sharon, Kamranpour, Naeimeh, Desai, Amrita J, Hosmer, Wylie, Ide, Susan, Avsar, Emin, Jensen, Michael Rugaard, Quadt, Cornelia, Liu, Manway, Dubinett, Steven M, Slamon, Dennis J

Volltext

Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer von Garon, Edward B., Pietras, Richard J., Finn, Richard S., Kamranpour, Naeimeh, Pitts, Sharon, Márquez-Garbán, Diana C., Desai, Amrita J., Dering, Judy, Hosmer, Wylie, von Euw, Erika M., Dubinett, Steven M., Slamon, Dennis J.

Volltext

Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell... von Garon, Edward B, Finn, Richard S, Hosmer, Wylie, Dering, Judy, Ginther, Charles, Adhami, Shahriar, Kamranpour, Naeimeh, Pitts, Sharon, Desai, Amrita, Elashoff, David, French, Tim, Smith, Paul, Slamon, Dennis J

Volltext

ERCC5 Is a Novel Biomarker of Ovarian Cancer Prognosis von WALSH, Christine S, OGAWA, Seishi, SANADA, Masashi, NANNYA, Yasuhito, SLAMON, Dennis J, KOEFFLER, H. Phillip, KARLAN, Beth Y, KARAHASHI, Hisae, SCALES, Daniel R, PAVELKA, James C, TRAN, Hang, MILLER, Carl W, KAWAMATA, Norihiko, GINTHER, Charles, DERING, Judy

Volltext

Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target von Fejzo, Marlena S., Dering, Judy, Ginther, Chuck, Anderson, Lee, Ramos, Lilian, Walsh, Christine, Karlan, Beth, Slamon, Dennis J.

Volltext

Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK von Fejzo, Marlena S., Ginther, Chuck, Dering, Judy, Anderson, Lee, Venkatesan, Natarajan, Konecny, Gottfried, Karlan, Beth, Slamon, Dennis J.

Volltext

A Collagen-Remodeling Gene Signature Regulated by TGF-β Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer von CHEON, Dong-Joo, YUNGUANG TONG, KARLAN, Beth Y, ORSULIC, Sandra, SIM, Myung-Shin, DERING, Judy, BEREL, Dror, XIAOJIANG CUI, LESTER, Jenny, BEACH, Jessica A, TIGHIOUART, Mourad, WALTS, Ann E

Volltext

Clinical evaluation of BCL-2/X.sub.L levels pre- and post- HER2-targeted therapy von Zoeller, Jason J, Press, Michael F, Selfors, Laura M, Dering, Judy, Slamon, Dennis J, Hurvitz, Sara A, Brugge, Joan S

Volltext